Ipilimumab and Nivolumab in Rare Tumors S1609: Neuroendocrine—Response

On Behalf of the S1609 Team

doi:10.1158/1078-0432.CCR-20-0790

Ipilimumab and Nivolumab in Rare Tumors S1609: Neuroendocrine—Response

On Behalf of the S1609 Team

Medicine, Hematology Oncology Division

Research output: Contribution to journal › Letter

Original language	English (US)
Pages (from-to)	2434
Number of pages	1
Journal	Clinical Cancer Research
Volume	26
Issue number	10
DOIs	https://doi.org/10.1158/1078-0432.CCR-20-0790
State	Published - May 15 2020

ASJC Scopus subject areas

Oncology
Cancer Research

Access to Document

10.1158/1078-0432.CCR-20-0790

Cite this

On Behalf of the S1609 Team (2020). Ipilimumab and Nivolumab in Rare Tumors S1609: Neuroendocrine—Response. Clinical Cancer Research, 26(10), 2434. https://doi.org/10.1158/1078-0432.CCR-20-0790

@article{99a2947c3c5e4a1599f8fdbb869643c3,

title = "Ipilimumab and Nivolumab in Rare Tumors S1609: Neuroendocrine—Response",

author = "{On Behalf of the S1609 Team} and Patel, {Sandip P.} and Megan Othus and Chae, {Young Kwang} and Razelle Kurzrock",

year = "2020",

month = may,

day = "15",

doi = "10.1158/1078-0432.CCR-20-0790",

language = "English (US)",

volume = "26",

pages = "2434",

journal = "Clinical Cancer Research",

issn = "1078-0432",

publisher = "American Association for Cancer Research Inc.",

number = "10",

}

TY - JOUR

T1 - Ipilimumab and Nivolumab in Rare Tumors S1609

T2 - Neuroendocrine—Response

AU - On Behalf of the S1609 Team

AU - Patel, Sandip P.

AU - Othus, Megan

AU - Chae, Young Kwang

AU - Kurzrock, Razelle

PY - 2020/5/15

Y1 - 2020/5/15

UR - http://www.scopus.com/inward/record.url?scp=85084785711&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85084785711&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-20-0790

DO - 10.1158/1078-0432.CCR-20-0790

M3 - Letter

C2 - 32414761

AN - SCOPUS:85084785711

VL - 26

SP - 2434

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 10

ER -